Fig. 2.

DARA-mediated ADCC based on CD16 expressing NK cells. A BCBL-1, GTO, and TY-1 cells were incubated with various concentrations of DARA, and co-cultured with ADCC-indicating Jurkat cells (E:T ratio = 1:5) for 18 h. Luciferase activity was measured. B, C, D, E) CFSE-labeled BCBL-1 cells were treated with IgG1 or DARA, co-cultured with CD16 + NK (N6) or CD16- NK (KHYG-1) cell lines at different E:T ratio for 4 h, and analyzed for dead BCBL-1 (CFSE⁺Ghost Dye⁺) cells by flow cytometry. F Up-regulation of CD107a after DARA treatment was analyzed by flow cytometry. G Percentages of CD56⁺CD107a⁺ cells after stimulation with DARA (n = 3). Data are presented as mean values ± standard error (SE). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 significant levels